New UK Board Candidate, sales pipeline progress and Unit Rights Issue
How does this Q&A work:
This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Speakers at this event:
7 Questions
March 21, 2025
Dear B+
- if not answered already in the presentation - please elaborate on how the new issuance is developing ?
maybe in a % split on how investors are buying shares and how close You are to main objective.
Kind regards Niels R
March 21, 2025
Can you please provide actual numbers in the sales pipeline, rather than percentages (which can be misleading)? How many from initial contact to sales?
March 21, 2025
When is the last date, to make a commitment, for subscription of new shares, when either not having enough rights, or not having rights at all?
March 20, 2025
Regarding the expected UK sales, are they going to be full sales, meaning that the given centre can provide Ayla CST training, for all it's patients, that would benifit from CST, or limited contracts, with a limited number of patients, being able to receive CST, via Ayla?
March 20, 2025
You expect a recurring multi years sales contract in Denmark, later this year. Can you for clearification, confirm the total number of municipalities, in Denmark, that have a contract for Ayla, and how many, that have a multi years contract on Ayla? And perhaps confirm, whether they have signed full contracts, based on their total amount of CST patients?
March 20, 2025
What kind of role, are Vishal going to play, in regard of Sales? Are Vishal going out proactive in sales, or are his role, only advisory board member?
March 20, 2025
Will this be the last share issue?